RTI Biologics (RTIX -12.7%) gets smacked today after its Q4 EPS came in-line with forecasts, but...

|About: RTI Surgical, Inc. (RTIX)|By:, SA News Editor

RTI Biologics (RTIX -12.7%) gets smacked today after its Q4 EPS came in-line with forecasts, but revenue misses analyst estimates on weakness in its surgical specialties and sports medicine businesses. The company also issued downbeat guidance, saying sales and profit during the first half of the year will be weak due to customer reaction to its FDA warning letter over contaminated human tissue implants.